Pantazaka, E.; Ntzifa, A.; Roumeliotou, A.; Lianidou, E.; Georgoulias, V.; Kotsakis, A.; Kallergi, G.
PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC). Biomedicines 2022, 10, 1893.
https://doi.org/10.3390/biomedicines10081893
AMA Style
Pantazaka E, Ntzifa A, Roumeliotou A, Lianidou E, Georgoulias V, Kotsakis A, Kallergi G.
PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC). Biomedicines. 2022; 10(8):1893.
https://doi.org/10.3390/biomedicines10081893
Chicago/Turabian Style
Pantazaka, Evangelia, Aliki Ntzifa, Argyro Roumeliotou, Evi Lianidou, Vassilis Georgoulias, Athanasios Kotsakis, and Galatea Kallergi.
2022. "PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC)" Biomedicines 10, no. 8: 1893.
https://doi.org/10.3390/biomedicines10081893
APA Style
Pantazaka, E., Ntzifa, A., Roumeliotou, A., Lianidou, E., Georgoulias, V., Kotsakis, A., & Kallergi, G.
(2022). PD-L1/pS6 in Circulating Tumor Cells (CTCs) during Osimertinib Treatment in Patients with Non-Small Cell Lung Cancer (NSCLC). Biomedicines, 10(8), 1893.
https://doi.org/10.3390/biomedicines10081893